HIV in Tanzania: Current Epidemiology and Learned Lessons from the Early Epidemic

1. HIV in Tanzania: Current Epidemiology and Learned Lessons from the Early Epidemic Dr. William P. Howlett Matthew P. Rubach, MD Dr. Neema W. Minja Department of Internal Medicine, KCMC KCMC/Duke Collaboration KCMC CLINICAL CONFERENCE 1ST JUNE 2016

3. EPIDEMIOLOGYTANZANIA/ SUB-SAHARAN AFRICA

4. THMIS SURVEY 2011/2 • Tanzanian HIV Prevalence 5.1% * Not statistically significant Tanzania HIV /AIDS & Malaria Indicator Survey 2011/1

5. Global AIDS Response Country Progress Report 2014

6. Global AIDS Response Country Progress Report 2014 UNAIDS GAP Report

8. HIV prevalence n general has decreased.... 8 regions report an increase: Ruvuma, Kagera, Kigoma, Rukwa, Mtwara, Kilimanjaro, Singida, & Arusha TACAIDS National Response Report 2012

9. High risk groups Global AIDS Response Country Progress Report 2014

10. Global AIDS Response Country Progress Report 2014

11. Global AIDS Response Country Progress Report 2014

12. Global AIDS Progress Report 2013 UNAIDS

13. Global AIDS Progress Report 2013 UNAIDS

14. UGANDA The HIV/AIDS Uganda country Progress Report 2014

15. The role of anti-retroviral agents in prevention of HIV

16. Prevention Efforts • Behavorial interventions: sex education/safe sex practices, counseling, safe infant feeding • Structural interventions: address gender and social inequality, needle exchange programs • Biomedical interventions: • Male circumcision • Microbicides • ARV: • Pre-Exposure Prophylaxis (PrEP) • Treatment as Prevention (TAP)

17. Pre-Exposure Prophylaxis • Indication: for high-risk populations who may be repeatedly exposed to HIV • Sero-discordant couples • Sex workers • Men who have sex with men (MSM) • IV drug users • Approach: • Step 1: confirm person is HIV-negative • Step 2: prescribe ARV (usually 1-2 agents, e.g., Tenofovir/Emtricitabine or Tenofovir alone) • Step 3: HIV test every 3 months

18. Data Supporting Use of PrEP

19. Trials with No Benefit to PrEP • FEM-PrEP • 1,951 women aged 18-35 years Kenya, South Africa and Tanzania • ‘High risk:’ >/=1 vaginal sex acts in previous 2 weeks or > 1 sex partner in previous month • Randomized to TDF/FTC vs. placebo: • Adherence self-report 95% • Pill count adherence 88% • Detection of TDF in patient plasma was 15-26%!!! • VOICE • 5,029 women aged 18-45 years South Africa, Uganda and Zimbabwe • Randomized to oral TDF vs. TDF/FTC vs. TDF gel vs. placebo: • Adherence self-report or pill count 84-91% • Detection was 29-40%!!! Van Damme et al, N Engl J Med 2012;367:411 Marazzo et al, N Engl J Med 2015;372:509

20. PrEP & Guidelines WHO • Oral pre-exposure prophylaxis with TDF or TDF/FTC for • Serodiscordant couples • MSM • Recommendation in place since 2012 TZ MoH • No recommendations for or against PrEP in 2015 NACP guidelines WHO, Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, 2013 Guidance on oral PrEP for serodiscordant couples and MSM at high risk of HIV, 2012

21. PrEPTAP • Role for PrEP in the era of Treatment as Prevention??? • HPTN 052: randomized serodiscordant couples to early ART vs. standard of care • Early ART group: hazard of 0.04 (95% CI 0.01-0.27) of transmitting HIV to the HIV-negative partner Cohen et al, N Engl J Med 2011;365:493

23. When to Start ART • Risk:benefit ratio of medications & costs of medications WHO GL CD4 threshold < 200 • Severe et randomized 816 Haitian adults with CD4 200-350 to early ART vs. Deferred until CD4 < 200 • 18 vs. 36 incident cases of TB (HR 2.0 [95% CI 1.2-3.6], p=0.01) • 6 vs. 23 deaths in early vs. deferred (HR 4.0 [95% CI 1.6-9.8] p=0.001) • Absolute Risk Reduction (ARR): 5.6%-1.5% = 4.1% • Number needed to treat (NNT): 1/ARR = 1/0.041 = 24 WHO 2010 CHANGED GUIDELINE ON ART INITIATION TO CD4 < 350 Severe et al, N Engl J Med 2010;363:3

24. INSIGHT START Study • 4865 adults with CD4 > 500 randomized to immediate ART vs. ART once CD4 < 350 • Composite endpoint: serious AIDS-related event, non-AIDS related event or death from any cause • Endpoint events: 42 (1.8%) of immediate group and 96 (4.1%) of delayed group • Hazard Ratio 0.43 (95% CI 0.30-0.62) p< 0.001 START Team, N Engl J Med 2015;373:795

25. 14 vs. 50 events HR 0.28 p < 0.001 12 vs. 21 events HR 0.58 p= 0.13 START Team, N Engl J Med 2015;373:795

26. TEMPRANO DESIGN • 2056 patients from Ivory Coast, 2x2 factorial design to assess • Early ART vs. Waiting for WHO criteria for ART • Isoniazid Preventive Therapy • Endpoint: AIDS-defining event, other serious complications (cancer, bacterial infections, TB) or death • Results: • TB & invasive bacterial disease: 42% and 27% of the primary endpoint events • Endpoint HR 0.56 (95% CI 0.41-0.76) early ART vs. deferred ART TEMPRANO ANRS, N Engl J Med 2015;373:808

27. PrEP in the Era of HIV-TAP Evolution of WHO guidance on CD4 thresholds for initiating ART: Current TZ NACP 2015 Guidance: • CD4 < 500 or Clinical Stage 3 or 4 AIDS • Initiate ART regardless of Clinical Stage or CD4 count in following scenarios: • TB co-infection (Stage 3 criterion) • Hepatitis B co-infection • High risk population: MSM, IVDU, sex worker, prisoner • Serodiscordant couples

28. Lessons learnt from the early epidemic

29. Biomarker of HIV Testing Programs: CD4 at Diagnosis Temporal trends in CD4 count at presentation to care in sub-Saharan Africa 2002-2012 Siedner et al, Clin Infect Dis 2015;60:1120

30. References • The third Tanzania HIV and Malaria Indicator Survey 2011 – 2012 (THMIS III) • Global AIDS Response country progress report 2014. The United Republic of Tanzania. • The GAP. UNAIDS. Beginning of the end of the AIDS epidemic. 2013 • The HIV and AIDS Uganda country progress report 2014 • National HIV and AIDS Response report 2012. Tanzania Mainland. TACAIDS • Global AIDS Response Country Progress Report 2014 • Boerma et al. Spread of HIV infection in a rural area in Tanzania. AIDS. 1999. Vol 13. No. 10. pg 1233 – 1240 • Fact Sheet: Njombe adolescents at a glance regional survey results 2010-2012. DHSTHMIS Adolescent